Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer (DEBIRITUX)

This study has been terminated.
(Terminated due to poor subject enrolment)
Biocompatibles UK Ltd
Information provided by (Responsible Party):
Dirk Arnold, Martin-Luther-Universität Halle-Wittenberg Identifier:
First received: January 27, 2010
Last updated: June 25, 2013
Last verified: June 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: September 2013
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)